作者: Jon Reynolds
DOI: 10.2147/DMSOTT.S4637
关键词:
摘要: Janumet(TM,) a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment patients with type 2 diabetes, that are inadequately controlled, either sitagliptin or metformin alone together in free-dose form. Sitagliptin, an inhibitor the enzyme DDP-4, assists diabetes mellitus to achieve glycemic control. It been shown be safe effective at 100 mg daily doses. The effect giving is thought have complimentary possibly additive on